从文档到记录再到智能：生命科学的下一个数字化前沿

The author still remembers one of his first projects in the life sciences industry.

At the time, the challenge was clear: regulatory submissions were created, reviewed, and managed across multiple functions, systems, and repositories. Teams were spending significant effort locating information, reconciling document versions, and coordinating communications with health authorities. The industry's focus was on digitizing submission dossiers and creating a single source of truth for regulatory content and correspondence throughout the drug development and approval lifecycle.

It was a transformational step.

For the first time, organizations could move away from fragmented paper-based processes toward integrated digital repositories that connected regulatory affairs, quality, clinical, safety, and manufacturing functions. Information became more accessible, traceable, and reusable across the enterprise.

However, this was only the beginning.

The Shift from Documents to Records

As the industry matured in its digital transformation journey, a new realization emerged: digitizing documents was valuable, but digitizing information was far more powerful.

Organizations began breaking down large documents into structured digital records. Instead of managing entire documents as a single unit, individual pieces of information became first-class business objects.

For example, rather than maintaining a user requirements specification as a static document, individual requirements could be captured, governed, approved, traced, and reused as discrete records.

This seemingly simple shift had profound implications.

Workflows could now operate at the level of a single information object rather than an entire document package. Traceability improved significantly. Compliance became more transparent. Data quality increased through standardization and validation rules. Most importantly, organizations gained the ability to automate decisions and processes at a level that was previously impossible.

The industry quietly transitioned from document-centric operations to record-centric operations.

And in doing so, it laid the foundation for the next wave of transformation.

Why AI Arrives at the Right Time

Today, AI stands at the doorstep of the life sciences industry.

Much of the current discussion focuses on AI as a productivity tool: drafting content, summarizing information, generating insights, or assisting knowledge workers. These capabilities undoubtedly create value.

Yet the author believes the bigger opportunity lies elsewhere.

AI is not merely seeking a role as a personal assistant.

It is seeking promotion to become an enterprise capability.

The true potential of AI emerges when it can operate across a landscape of trusted, structured, and governed digital records. The years invested in digitizing documents and subsequently transforming them into interconnected records have created the very foundation AI requires to deliver enterprise-scale value.

Across the drug lifecycle, AI has the potential to accelerate and enhance:

• Research and target identification
• Clinical trial design and execution
• Regulatory authoring and submissions
• Quality management and compliance
• Pharmacovigilance operations
• Manufacturing and supply chain processes

The industry's previous digital investments have paved the road for this opportunity. However, success will not be determined by technology alone.

The Governance Imperative

As excitement around AI grows, organizations face a familiar challenge: how does the industry innovate rapidly while maintaining the rigorous standards expected within a highly regulated industry?

The answer is not unrestricted experimentation. Nor is it excessive bureaucracy.

The answer lies somewhere in between.

Organizations need governance frameworks that provide clarity without creating friction. They need delivery methodologies that encourage innovation while ensuring patient safety, data integrity, compliance, and accountability.

In other words, they need guided innovation.

Guided innovation establishes the guardrails required for responsible adoption while preserving the creativity and speed necessary to unlock value.

This includes:

• Clear AI governance structures and accountability models
• Risk-based assessment frameworks
• Defined stage gates across the AI development lifecycle
• Validation and monitoring approaches appropriate to AI-enabled solutions
• Data governance and model governance practices
• Compliance, ethics, and transparency standards
• Continuous performance measurement and oversight

Just as software development matured through structured delivery methodologies, AI adoption will require its own evolution toward repeatable, scalable, and governable delivery frameworks.

Building the AI Operating Model for Pharma

The next strategic question facing life sciences leaders is not whether AI will create value. The question is how organizations will industrialize AI adoption responsibly.

Leading companies will move beyond isolated use cases and pilot programs. They will establish enterprise capabilities that integrate governance, methodology, technology, compliance, and business ownership into a coherent operating model.

This represents an important leadership opportunity.

The future of AI in life sciences will not be shaped solely by data scientists or technology teams. It will be shaped by leaders who can bridge innovation and compliance, speed and control, experimentation and accountability.

Those leaders will help define how AI is developed, governed, validated, deployed, and continuously monitored across the organization.

An Exciting Time for Our Industry

Looking back, the progression feels remarkably logical. We began by digitizing documents. We then transformed those documents into structured digital records. Today, we stand ready to unlock intelligence from those records through AI. Each stage built upon the previous one.

Each step increased the value of information.

And each transformation brought us closer to a future where knowledge can move faster than ever before across the drug lifecycle.

For life sciences organizations, the opportunity is enormous. But realizing that opportunity will require more than innovative technology. It will require thoughtful governance, modern delivery methodologies, and a commitment to guided innovation.

What an exciting time to be part of this journey.

The next chapter of life sciences transformation is not simply about becoming more digital. It is about becoming intelligently digital.